PATENT CLAIM ANALYSIS

Application Number: 15946955
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "395000"]

Abstract:
The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Claim (Index 8):
The method of  claim 7 , wherein the an anti-tumor agent is selected from the group consisting of antimetabolites, DNA-fragmenting agents, DNA-crosslinking agents, intercalating agents, protein synthesis inhibitors, topoisomerase I poisons, topoisomerase II poisons, microtubule-directed agents, kinase inhibitors, polyphenols, hormones, hormone antagonists, death receptor agonists, immune checkpoint inhibitors, anti-programmed cell death 1 (PD-1) receptor antibodies and anti-programmed cell death ligand 1 (PD-L1) antibodies.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.04348
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15255910', '15178390', '15683408', '12763991', '15137323']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7333124937864816
- 35 USC 102 Novelty (BERT): 0.587735205892921
- Combined Prediction Score: 0.7187547649971255
- Mean Citation Score: 303.269732
- Max Citation Score: 502.8837
- Similarity Product: 437.5503356708944

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test